Activity

Activity ID

12946

Expires

November 24, 2024

Format Type

Journal-based

CME Credit

1

Fee

$30

CME Provider: JAMA Oncology

Description of CME Course

This cohort study examines the ability of patients receiving chimeric antigen receptor T-cell treatments to mount T-cell immunity in response to messenger RNA vaccines for severe acute respiratory syndrome coronavirus 2 despite substantial B-cell depletion.

Disclaimers

1. This activity is accredited by the American Medical Association.
2. This activity is free to AMA members.

Register for this Activity

ABMS Member Board Approvals by Type
More Information
Commercial Support?
No

NOTE: If a Member Board has not deemed this activity for MOC approval as an accredited CME activity, this activity may count toward an ABMS Member Board’s general CME requirement. Please refer directly to your Member Board’s MOC Part II Lifelong Learning and Self-Assessment Program Requirements.

Educational Objectives

To identify the key insights or developments described in this article

Keywords

Coronavirus (COVID-19), Oncology, Targeted and Immune Cancer Therapy, Vaccination

Competencies

Medical Knowledge

CME Credit Type

AMA PRA Category 1 Credit

DOI

10.1001/jamaoncol.2021.6030

View All Activities by this CME Provider

The information provided on this page is subject to change. Please refer to the CME Provider’s website to confirm the most current information.